Intravenous immunoglobulin therapy in rheumatic diseases.
about
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future PerspectivesNatural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune diseaseAnalysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionationB cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.Intravenous immunoglobulin as clinical immune-modulating therapy.Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.IVIG regulates the survival of human but not mouse neutrophils.Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2.Intestinal pseudo-obstruction in patients with systemic lupus erythematosus: a real diagnostic challenge.Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management.Natural IgM in immune equilibrium and harnessing their therapeutic potential.Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation.Intravenous immunoglobulin in the management of lupus nephritis.Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin.Critical role of activation induced cytidine deaminase in experimental autoimmune encephalomyelitis.Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic diseaseAffinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity.IVIg attenuates complement and improves spinal cord injury outcomes in mice.Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patientsProtective Roles of Natural IgM Antibodies.The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies.Clinical use of polyvalent immunoglobulinsPolyvalent immunoglobulins: challenges and perspectivesTargeting B cells and autoantibodies in the therapy of autoimmune diseases.The protective role of immunoglobulins in fungal infections and inflammation.Pharmacokinetic modeling of therapies for systemic lupus erythematosus.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.IVIG-mediated effector functions in autoimmune and inflammatory diseases.Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches.The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations.Specificity of regulatory T cells that modulate vascular inflammation.Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease.Vasculitides throughout history and their clinical treatment today.Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice.Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.Reply to — IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientistIntravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patientsInterferon-α Inhibition by Intravenous Immunoglobulin Is Independent of Modulation of the Plasmacytoid Dendritic Cell Population in the Circulation: Comment on the Article by Wiedeman et alNatural Autoantibodies to Fcγ Receptors in Intravenous Immunoglobulins
P2860
Q26774815-C700706F-598B-48CE-9DA0-D027119BE7A5Q27021242-C5B0F900-81FB-481D-8BA3-B7CF47E6B822Q28728886-0BDA2767-17DD-420A-A409-E775DFF52CC3Q33403107-71EFA43B-04D8-4B4B-9809-4BB27341FE07Q33420267-03BE7718-9165-4DDE-9172-56C86C4F875FQ33420853-6D675DFE-3571-4483-869D-D5147F000F10Q33683531-149E1623-13D6-4561-8623-D039463D0C2CQ34058507-1BC4B76D-68CB-42DB-A1A6-926948415264Q34093954-C7723B6C-4AB9-4A88-80C7-2014AE348D80Q34476952-6B2CBCFC-7002-4A54-BFC0-267D0E84BE67Q35694606-052D78F4-5F12-4742-985C-4CF86980B502Q36085055-9121CDA3-38C3-4D71-A074-A38C0236FAA2Q36302368-6C6E7710-8E87-4ACC-9533-D0F4EB2899A9Q36500575-92E97CE2-5B86-474E-A9C4-4FD689A37390Q36634895-50D81788-FFEA-4935-9694-53DB127ABD58Q36757069-A5CBB917-8510-410C-A90B-7B9ACF622D4EQ37027756-AC5A77CB-758E-400D-883B-8D4E164A3683Q37062115-2292FFDA-EF2B-48EE-8E9E-DBD8B8D45640Q37732919-2E2BF509-824B-4DE5-B087-E4184E30A1F1Q38008368-A9DAC913-56B8-4849-B398-3B35E2CAABF4Q38117686-B041863E-0455-4964-92D6-E89EFD7D86EAQ38170872-72C2C9B4-C59F-41C2-B851-698CD75EB903Q38170873-6D53B3F1-A648-4945-8A86-B1441CA27771Q38207937-BBE23464-EAC7-4F37-98ED-45C51C6F3CE6Q38268922-8FA8C350-7B35-4927-875A-A8DA09F595ABQ38542910-E8DEA3B6-F26B-4E83-BD0A-AE7A2E574E8FQ38615353-026186CE-FD94-4737-BA0D-6F092CDB8FE6Q38699812-5A7254C5-628D-4C9C-8D80-6C5868984AF3Q40762677-8F76A25B-DB6F-4795-B21A-8D98A11B1746Q42368365-B431BB18-EE26-4166-B2BD-92B3C4474D28Q43707482-A54B644F-A263-4AF2-B30E-74ED0A7C528AQ46657722-81468028-0269-4ED3-A397-651E782023E2Q47882674-0EA6737A-A139-4F33-9555-E7D7AABEA12FQ48594996-B67129CD-814C-4437-9D00-40E7F8D2AEBAQ49644555-13E4597A-5CDF-4E95-92AF-85DC484C740BQ50193260-47DAF4C0-7E10-48D1-97B5-4D22ED14FD1DQ57253422-DE48FC0D-7517-4130-B9AD-D691C65532F8Q58861212-94775FB9-E3F6-4A0C-8DF5-419794D872FBQ58861214-D7B25057-283D-46E9-9A97-1D0F1A95BDD9Q58861216-09E0A475-F4A0-46A4-AC24-FAE8229AB1C0
P2860
Intravenous immunoglobulin therapy in rheumatic diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intravenous immunoglobulin therapy in rheumatic diseases.
@en
Intravenous immunoglobulin therapy in rheumatic diseases.
@nl
type
label
Intravenous immunoglobulin therapy in rheumatic diseases.
@en
Intravenous immunoglobulin therapy in rheumatic diseases.
@nl
prefLabel
Intravenous immunoglobulin therapy in rheumatic diseases.
@en
Intravenous immunoglobulin therapy in rheumatic diseases.
@nl
P2860
P356
P1476
Intravenous immunoglobulin therapy in rheumatic diseases.
@en
P2093
Vir Singh Negi
P2860
P2888
P304
P356
10.1038/NRRHEUM.2011.61
P407
P577
2011-05-10T00:00:00Z